Organization
Central Hospital Affiliated to Shandong First Medical University, Jinan, China
6 abstracts
Abstract
Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results.Org: Zhejiang Cancer Hospital, Hangzhou, China, Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, China, The First Hospital of China Medical University, Shenyang, China, The Affiliated Cancer Hospital of Xinjiang Medical University, Wulumuqi, China, Second Affiliated Hospital of Nanchang University, Nanchang, China,
Abstract
First-in-human phase 1 study of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, West China Hospital, Sichuan University, Chengdu Origen Biotechnology, China National Biotec Group,
Abstract
Phase I summary of the HB0025 efficacy and safety to the heavily pretreated non-small cell lung cancer (NSCLC) population.Org: Fudan University Shanghai Cancer Center, Phase I Cinical Trial Center, Central Hospital Affiliated to Shandong First Medical University, Jinan, China, Jinan Central Hospital, Shandong University, Shandong University of Traditional Chinese Medicine Affiliated Hospital,
Abstract
Safety and efficacy of HB0025, an anti-PD-1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: Preliminary results from an FIH trial.Org: Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center, Central Hospital Affiliated to Shandong First Medical University, Jinan, China, Next Oncology Virginia and Virginia Cancer Specialists, Linyi Cancer Hospital,
Abstract
Efficacy and safety of KN026 in combination with KN046 in patients with locally advanced unresectable or metastatic HER2-positive other solid tumors.Org: Beijing Cancer Hospital & Institute, Cancer Hospital of Shantou University Medical College, Central Hospital Affiliated to Shandong First Medical University, Jinan, China, Luoyang Center Hospital, Department of Medical Oncology, Zibo Municipal Hospital, Zibo, China,
Abstract
Updated results of first-line serplulimab versus placebo plus chemotherapy in PD-L1–positive esophageal squamous cell carcinoma: A randomized, double-blind, multicenter phase 3 study (ASTRUM-007).Org: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China, Xingtai People's Hospital, Xingtai, China, Shandong First Medical University Cancer Hospital, Shandong Cancer Hospital, Jinan, China, Central Hospital Affiliated to Shandong First Medical University, Jinan, China,